Aspire BioPharma

Aspire BioPharma

Growth Stage

Disruptive technology that improves medicine effectivess safely and rapidly

Disruptive technology that improves medicine effectivess safely and rapidly

Overview

Raised to Date: Raised: $226,792

Total Commitments ($USD)

Platform

Republic

Start Date

10/31/2023

Close Date

01/31/2024

Min. Goal
$150,000
Max. Goal
$5,000,000
Min. Investment

$500

Security Type

Equity - Preferred

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$0.80

Pre-Money Valuation

$352,000,000

Rolling Commitments ($USD)

Status
Funded
Reporting Date

02/03/2024

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$2,492

# of Investors

138

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2021

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Humacao, Puerto Rico

Business Type

Growth

Aspire BioPharma, with a valuation of $352 million, is raising funds on Republic. The company has developed its patent-protected disruptive technology that improves the effectiveness of medicine safely and rapidly. Aspire BioPharma’s technology enables the medicine to flow into the bloodstream directly instead of going through the digestive tract and impacting the liver. The first product of Aspire BioPharma will be Instaprin, a novel soluble formulation of aspirin for stroke emergencies and pain management. Kraig Higginson founded Aspire BioPharma in September 2021. The current crowdfunding campaign has a minimum target of $150,000 and a maximum target of $5 million. The campaign proceeds will be used for GMP batch production and clinical trials, professional services, and working capital.

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$0

$0

COGS

$0

$0

Tax

$626

$626

 

 

Net Income

$-597,117

$-464,173

Summary Balance Sheet

FY 2022 FY 2021

Cash

$38

$185,496

Accounts Receivable

$0

$0

Total Assets

$4,917,644

$185,496

Short-Term Debt

$193,881

$117,169

Long-Term Debt

$3,852,552

$0

Total Liabilities

$4,046,433

$117,169

Financials as of: 10/31/2023
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Aspire BioPharma on Republic 2023
Platform: Republic
Security Type: Equity - Preferred
Valuation: $352,000,000
Price per Share: $0.80

Follow company

Follow Aspire BioPharma on Republic 2023

Buy Aspire BioPharma's Deal Report

Warning: according to the close date for this deal, Aspire BioPharma may no longer be accepting investments.

Aspire BioPharma Deal Report

Get KingsCrowd’s comprehensive report on Aspire BioPharma including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Aspire BioPharma is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Aspire BioPharma deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge